Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Pneumococcal Vaccine Market Size Forecast: How Large Could The Market Become By 2030?
The pneumococcal vaccine market has experienced significant expansion in recent years, with its value projected to rise from $9.4 billion in 2025 to $9.94 billion by 2026, reflecting a compound annual growth rate of 5.7%. This past growth has been driven by several key factors, including a high burden of childhood pneumonia, the integration of these vaccines into national immunization schedules, robust backing from international health bodies, increased public awareness of invasive pneumococcal disease, and the well-documented effectiveness of PCV vaccines.
The pneumococcal vaccine market is projected to experience robust expansion over the coming years, reaching a valuation of $12.76 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is fueled by the introduction of next-generation PCV vaccines, broader adult vaccination recommendations, improved healthcare accessibility in emerging markets, heightened concerns over antimicrobial resistance, and increased government investment in preventive immunization programs. Key trends shaping this period include the development of conjugate vaccines targeting a wider range of serotypes, a stronger emphasis on immunization initiatives for both children and the elderly, growing adoption of combination and booster vaccination approaches, enhanced public-private collaborations to expand vaccine coverage, and a general shift toward preventive healthcare and the integration of vaccines into national immunization schedules.
Download A Free Sample Report For Comprehensive Market Insights:
Pneumococcal Vaccine Market Growth Drivers And Industry Catalysts
The anticipated expansion of the pneumococcal vaccine market is being driven by the rising incidence of pneumococcal contamination. This type of contamination encompasses infections caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus, which includes conditions like pneumonia, bloodstream infections, ear infections, and sinus infections. By triggering the production of antibodies that target pneumococcal bacteria, the vaccine works to diminish or eliminate disease-causing organisms and their toxins, providing protection against various pneumococcal infections for children, the elderly, and individuals with compromised immune systems. For example, data from July 2025, released by the Immunisation Coalition—an independent non-profit charity based in Australia—indicates that cases of invasive pneumococcal disease (IPD) have risen consistently year over year, climbing from 1,869 in 2022 to 2,265 in 2023, and further increasing to 2,379 in 2024. Consequently, this growing prevalence of pneumococcal contamination is fueling momentum in the pneumococcal vaccine market.
Pneumococcal Vaccine Market Segment Analysis And Revenue Opportunities
The pneumococcal vaccine market covered in this report is segmented –
1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products
2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous
3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels
4) By End User: Pediatrics, Adults
Subsegments:
1) By Prevnar 13: Pediatric Formulation, Adult Formulation
2) By Synflorix: Pediatric Formulation, Adult Formulation
3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes
4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines
Pneumococcal Vaccine Market Trends Influencing Long-Term Demand
Key players in the pneumococcal vaccine market are developing new products to enhance their competitive edge and profitability. For example, in July 2023, Merck & Co Inc., a pharmaceutical company headquartered in the United States, launched the V116 vaccine. This vaccine is specifically designed to address eight distinct serotypes of Streptococcus pneumoniae that are most commonly linked to pneumococcal disease in adults. V116 has demonstrated superior immunogenicity compared to other pneumococcal vaccines across a range of serotypes in adult populations, and it has elicited robust immune responses in both individuals who have never been vaccinated and those who have received prior vaccinations. The U.S. Food and Drug Administration (FDA) has granted V116 breakthrough therapy designation, and it is currently undergoing Phase 3 clinical trials.
Pneumococcal Vaccine Market Leading Players Shaping Industry Direction
Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE
Access The Complete Pneumococcal Vaccine Market Report:
Pneumococcal Vaccine Market Geographic Distribution And Regional Opportunities
North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model